https://www.selleckchem.com/pr....oducts/rucaparib.htm
Tacrolimus pharmacokinetics in obese (Ob) patients has been poorly studied. In this article, the authors explored the impact of obesity on tacrolimus exposure in kidney transplant recipients (KTRs) and estimated a more suitable initial dosage in this population. A retrospective, observational, monocentric case-control study was performed in obese KTRs (BMI 30 kg/m2) who received tacrolimus between 2013 and 2017 (initial dose 0.15 mg/kg/d) (actual weight). Nonobese (Nob) controls (BMI 30 kg/m2) were matched for age and sex. We
Like
Comment
Share
